Blood DNA sequencing matched 88% of clonal mutations in metastatic tumors
DNA sequencing of blood samples matched 88% of clonal somatic mutations and 80% of copy number alterations found in paired tumor biopsies from 41 patients with metastatic prostate or breast cancers. Clonal somatic mutations are acquired DNA changes shared across a tumor's cancer cells; copy number alterations are gains or losses of DNA sections. Published in Nature Communications on 6 November 2017, the study compared whole-exome sequencing of cell-free DNA, DNA circulating outside cells in blood, with sequencing of matched tumor biopsies. All 41 patients had ≥10% tumor-derived cell-free DNA.
Whole-exome sequencing reads the protein-coding portions of DNA. The study examined how closely the tumor information obtained from blood agreed with that obtained from a biopsy, a question the authors said remained uncertain across the genome.
The researchers introduced ichorCNA, software that estimates how much cell-free DNA comes from a tumor without needing prior knowledge of the tumor's mutations. It uses whole-genome sequencing at 0.1× coverage, a sparse reading across the genome, to measure tumor content before more comprehensive profiling.
They applied ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample from each patient, 34% had ≥10% tumor-derived cell-free DNA. That was sufficient for standard coverage whole-exome sequencing. The method therefore provided a way to identify patients eligible for comprehensive tumor DNA profiling from blood.
The paired comparison in 41 patients also found agreement between blood and biopsy results for mutational signatures, patterns of DNA changes, and neoantigens, altered molecules that the immune system can recognize. The reported agreement came from patients whose blood samples met the ≥10% tumor-content threshold; that threshold was reached by 34% of patients in the larger group's earliest tested samples.